Work Sustainability Among Male Cancer Survivors After Returning to Work

Background: Few studies have investigated the work continuance rate among cancer survivors after return to work (RTW). The objective of this study was to clarify work sustainability after RTW among Japanese male cancer survivors. Methods: We collected data on male cancer survivors from an occupation...

Full description

Bibliographic Details
Main Authors: Motoki Endo, Yasuo Haruyama, Go Muto, Kosuke Kiyohara, Tetsuya Mizoue, Noriko Kojimahara, Naohito Yamaguchi
Format: Article
Language:English
Published: Japan Epidemiological Association 2018-02-01
Series:Journal of Epidemiology
Subjects:
Online Access:https://www.jstage.jst.go.jp/article/jea/28/2/28_JE20160152/_pdf
Description
Summary:Background: Few studies have investigated the work continuance rate among cancer survivors after return to work (RTW). The objective of this study was to clarify work sustainability after RTW among Japanese male cancer survivors. Methods: We collected data on male cancer survivors from an occupational health register. Inclusion criteria were as follows: employees who returned to work after an episode of sick leave due to clinically certified cancer diagnosed between January 1, 2000 and December 31, 2011. Results: Of 1,033 male employees who were diagnosed with cancer, 786 employees (76.1%) returned to work after their first episode of sick leave due to cancer. Work continuance rates among all subjects were 80.1% 1 year after RTW and 48.5% 5 years after RTW. The mean duration of work after RTW was 4.5 years. The work continuance rates varied significantly by cancer type. The “Lung” and “Hepatic, Pancreatic” cancer groups had the shortest duration of work (0.9 year after RTW). Conclusions: Of workers who returned to work after their first episode of leave after cancer, 50% continued to work after 5 years in large-scale companies. There was a steep decrease in work continuance rates during the first year after RTW, with considerable differences according to cancer site.
ISSN:0917-5040
1349-9092